/AVXL

Anavex Life Sciences Corp

AVXL

$2.62USD↓-1.50%-0.04 today

MARKET CAP

242.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$2

$10

AI Summary

Stalk

TrimMedium

AVXL remains entrenched in a Stage 4 decline with active lower highs and lower lows under declining EMAs. Both medium-term and long-term directional biases are bearish, and with price trading near support and below key EMAs, execution should be deferred until rallies into the declining 9/21 EMA resistance zone for a rejection-based trim entry.

↑Focus on novel Alzheimer’s and CNS drugs addresses unmet market need
↑PVG proxy campaign could install experienced management, aiding strategy execution
↓Deeply negative earnings yield and weak profitability factors raise financial concerns

Full analysis →

Min Company Value

AI View

Min Insiders / Ticker

Hide Automated (10b5-1)

Date Range

Insider Trades3 trades

Date↓	Side	Ticker↕	Insider↕	Role↕	Shares↕	Price↕	Mkt Cap↕	52W High↕	52W Low↕	Value↕	% Chg↕	Rule↕	AI View↕
Sep 11, 2025	Buy	AVXL	Christopher U Missling	President and CEO	332,548	$7.02	$242.9M	-74.76%	+16.19%	$2.3M	+1.36%	—	Trim
Mar 24, 2025	Buy	AVXL	Christopher U Missling	President and CEO	782,497	$4.06	$242.9M	-74.76%	+16.19%	$3.2M	+7.25%	—	Trim
Mar 28, 2024	Sell	AVXL	Christopher U Missling	President and CEO	146,760	$3.22	$242.9M	-74.76%	+16.19%	$471.8K	+0.00%	—	Trim